EUVIMEDEUVIMED entdecken
Crossref

45,X/46, XY mosaicism: Clinical manifestations and long term follow‐up

Ebba Alkhunaizi iD, Jenna Plamondon Albrecht, Mahmoud Aarabi, Selma F Witchel, Diane Wherrett, Riyana Babul-Hirji, Annie Dupuis, Lyne Chiniara, Eric Chater-Diehl, Mary Shago, Cheryl Shuman, Aleksandar Rajkovic und 2 weitere

American Journal of Medical Genetics Part A · 2024-03 · 194 (3)

DOI: 10.1002/ajmg.a.63451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 26.10.2023. Verfasst von Ebba Alkhunaizi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canad…. Hauptthemen laut MEDLINE: Turner Syndrome, Gonadal Dysgenesis, Mixed, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Rare Disease Foundation and the BC Children's Hospital Foundation, Rare Disease Foundation, BC Children's Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

45,X/46,XY chromosomal mosaicism presents a range of clinical manifestations, including phenotypes from Turner syndrome through genital abnormalities to apparently unaffected phenotypic males; however, the full clinical spectrum has not yet been fully delineated since prior studies on the clinical phenotype and associated risk of gonadal tumors included small cohorts and limited follow‐up. To better describe the clinical manifestations and long‐term outcome of patients with 45,X/46,XY mosaicism. We conducted a retrospective chart review of patients with 45,X/46,XY from three health centers (Hospital for Sick Children and Mount Sinai Hospital in Canada, and University of Pittsburgh Medical Center in United States). Of 100 patients with 45,X/46,XY karyotype, 47 were raised as females and 53 as males. Females were significantly shorter than males ( p = 0.04) and height Z ‐score was significantly decreased with age for both genders ( p = 0.02). Growth hormone (GH) treatment did not result in a significant height increase compared to the untreated group ( p = 0.5). All females required puberty induction in contrast to majority of males. Five females were diagnosed with gonadal tumors, while no males were affected. Around 58% of patients exhibited at least one Turner syndrome stigmata. This study expands the clinical spectrum, long‐term outcomes, and associated tumor risk in a large cohort of patients with 45,X/46,XY mosaicism. Additionally, it highlights our experience with GH therapy and prophylactic gonadectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Turner SyndromeGonadal Dysgenesis, MixedNeoplasmsChildHumansMaleFemaleMosaicismFollow-Up StudiesRetrospective StudiesPhenotype

Stichwörter der Autor:innen

Turner syndromeabnormal genitaliagonadal malignancygrowthinfertilityprenatal diagnosis

Autor:innen und Institutionen

  • Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Cancer Risk and Prevention Clinic, Outpatient Care, Maine Health, Portland, Maine, USA.
  • UPMC Medical Genetics & Genomics Laboratories, UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA.
  • Departments of Pathology, and Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Ebba Alkhunaizi, David Chitayat

Förderung

  • Rare Disease Foundation and the BC Children's Hospital Foundation
  • Rare Disease Foundation
  • BC Children's Hospital Foundation

Zitieren

APA

Alkhunaizi, E., Albrecht, J. P., Aarabi, M., Witchel, S. F., Wherrett, D., Babul-Hirji, R., Dupuis, A., Chiniara, L., Chater-Diehl, E., Shago, M., Shuman, C., Rajkovic, A., Yatsenko, S. A., & Chitayat, D. (2024). 45,X/46, XY mosaicism: Clinical manifestations and long term follow‐up. American Journal of Medical Genetics Part A, 194(3). https://doi.org/10.1002/ajmg.a.63451

Vancouver

Alkhunaizi E, Albrecht JP, Aarabi M, Witchel SF, Wherrett D, Babul-Hirji R, et al. 45,X/46, XY mosaicism: Clinical manifestations and long term follow‐up. American Journal of Medical Genetics Part A. 2024;194(3). doi:10.1002/ajmg.a.63451

BibTeX
@article{Alkhunaizi2024,
  author = {Alkhunaizi, Ebba and Albrecht, Jenna Plamondon and Aarabi, Mahmoud and Witchel, Selma F and Wherrett, Diane and Babul-Hirji, Riyana and Dupuis, Annie and Chiniara, Lyne and Chater-Diehl, Eric and Shago, Mary and Shuman, Cheryl and Rajkovic, Aleksandar and Yatsenko, Svetlana A and Chitayat, David},
  title = {45,X/46, XY mosaicism: Clinical manifestations and long term follow‐up},
  journal = {American Journal of Medical Genetics Part A},
  year = {2024},
  volume = {194},
  number = {3},
  doi = {10.1002/ajmg.a.63451}
}
Kostenlos starten →